Vacancy in Glenmark pharmaceuticals Ltd. Walk-in on 12th may 2024

Vacancy in Glenmark pharmaceuticals Ltd. Walk-in on 12th may 2024 for multiple positions.

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India.

Glenmark Pharmaceuticals was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer. He named the company after his two sons. The company initially sold its products in India, Russia, and Africa. The company went public in India in 1999, and used some of the proceeds to build its first research facility. Saldanha’s son Glenn took over as CEO in 2001, having returned to India after working at PricewaterhouseCoopers. By 2008 Glenmark was the fifth-biggest pharmaceutical company in India. By 2011 the founder of the company was one of the richest men in India, and Glenmark had worldwide sales of $778 million, a 37% increase over the last year’s sales; the growth was driven by Glenmark’s entry into the US and European generics markets. In the mid-2010s the generics industry in general began transitioning to the end of an era of giant patent cliffs in the pharmaceutical industry; patented drugs with sales of around $28 billion were set to come off patent in 2018, but in 2019 only about $10 billion in revenue was set to open for competition, and less the next year. Companies in the industry responded with consolidation or trying to generate new, patented drugs. Glenn Saldanha took the company down the path of seeking innovation, which was controversial within the company and with shareholders. The company focused on new drugs and biosimilars in the fields of cancer, dermatology and respiratory diseases, which it sought to monetize by partnering with major pharmaceutical companies. In 2016 it had four such drugs in clinical trials. Its R&D developed a drug to treat asthma and COPD and licensed this to North America and Japan. It also licensed out a new diabetes drug to the German Merck. For the financial year 2016–2017 its sales were around 81 billion INR (ca. $1.25 billion), making it the fourth-biggest Indian pharmaceutical company.

More about company

http://www.glenmarkpharma.com/

 

vacancy

Vacancy details –

Department – QC, Production, packaging

Designation – Senior officer/ Officer

Qualification – Any Graduates/ Any postgraduate

Experience – 03 to 07 years

 

Similar job’s

Job vacancy in Glenmark pharmaceuticals Ltd. Walk-in on 19th may 2024

Glenmark Pharmaceuticals was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer. He named the company after his two sons. The company initially sold its products in India, Russia, and Africa. The company went public in India in 1999, and used some of the proceeds to build its first research facility. Saldanha’s son Glenn took over as CEO in 2001, having returned to India after working at PricewaterhouseCoopers. By 2008 Glenmark was the fifth-biggest pharmaceutical company in India. By 2011 the founder of the company was one of the richest men in India, and Glenmark had worldwide sales of $778 million, a 37% increase over the last year’s sales; the growth was driven by Glenmark’s entry into the US and European generics markets. In the mid-2010s the generics industry in general began transitioning to the end of an era of giant patent cliffs in the pharmaceutical industry; patented drugs with sales of around $28 billion were set to come off patent in 2018, but in 2019 only about $10 billion in revenue was set to open for competition, and less the next year. Companies in the industry responded with consolidation or trying to generate new, patented drugs. Glenn Saldanha took the company down the path of seeking innovation, which was controversial within the company and with shareholders. The company focused on new drugs and biosimilars in the fields of cancer, dermatology and respiratory diseases, which it sought to monetize by partnering with major pharmaceutical companies. In 2016 it had four such drugs in clinical trials. Its R&D developed a drug to treat asthma and COPD and licensed this to North America and Japan. It also licensed out a new diabetes drug to the German Merck. For the financial year 2016–2017 its sales were around 81 billion INR (ca. $1.25 billion), making it the fourth-biggest Indian pharmaceutical company.

Important details-

Location – Indore

Selection process – The selection will be on the basis of interview

Mode of interview – Face to face

Interview rounds of interview- HR

Walk-in interview details –

Date- 12th may 2024

Time- 09 Am to 12 Pm

Venue – Glenmark pharmaceuticals Ltd. Plot no -2 , phase II , pharma zone, ISEZ, pithampur, Madhya Pradesh- 454775

For more job related updates joined WhatsApp group

https://chat.whatsapp.com/KCk1lRtEdlJEJYDBTQNc9i

 

 

 

Leave a comment